ConcertAI has entered a multi-year partnership with Bayer to advance precision oncology through its Translational360 and AI SaaS solutions.
The solutions, driven by artificial intelligence and machine learning (AI/ML) insights, aim to expedite clinical development in precision oncology.
The collaboration will fully leverage ConcertAI’s Translational360, a newly launched integrated research-grade longitudinal clinical molecular database.
The database accesses the CancerLinQ network, which comprises de-identified cancer patient data from over nine million records across all 50 states in the US.
ConcertAI CEO Jeff Elton said: “This partnership furthers causal biological inferences where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster.
“This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modelling of likely success and benefit, informing program priority and clinical study design.”
Translational360 integrates clinical, genomic, transcriptomic, and whole-slide imaging data from comprehensive molecular testing.
The integration provides insights crucial for understanding disease molecular mechanisms and patient response variability, which are essential for developing new therapeutics.
The advanced AI and integrated data solutions will help select programmes and design trials informed by multi-modal, multi-genomic, and transcriptomic data.
Bayer pharma R&D data science and AI head Sai Jasti said: “As cancer rates continue to rise, we’re committed to advancing next-generation solutions that can speed up drug discovery and clinical development, enabling us to bring precision oncology treatments to patients faster.
“By combining ConcertAI’s powerful data solutions with Bayer’s scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.”
ConcertAI is a leader in predictive and generative AI SaaS and multi-modal real-world data research solutions for healthcare and life sciences.
The company collaborates with over 46 biomedical innovators, 2,000 healthcare providers, and medical societies to accelerate insights and outcomes for patients
Based in Cambridge, MA, the company has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo.
ConcertAI chief revenue officer Claudio D’Ambrosio said: “More AI-designed new molecular entities are progressing faster in first-in-human trials, which is a great milestone.
“Our entire R&D process has been historically built on studying controlled cell lines and animal models that don’t reflect the interspecies differences, the physiology, and the different biological barriers we have in humans.
“We are flipping this paradigm on its head. We need to start with human cancer genomes and phenotypes and ‘reverse translate.’ Unlike only a few years ago, we now have powerful human data.”
